Catherine Moukheibir
CIK: 0001772130
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Jun 17, 2026MLTX
MoonLake Immunotherapeutics
Award(A)DirectOption to Buy
22.2K shares- - Jun 16, 2026IRWD
IRONWOOD PHARMACEUTICALS INC
Award(A)Direct63.5K shares- - Jul 3, 2025MLTX
MoonLake Immunotherapeutics
Exercise(M)Direct23.5K shares- - Jul 3, 2025MLTX
MoonLake Immunotherapeutics
Sale(S)Direct23.5K shares at avg. $48.79$1.1M - Jun 10, 2025IRWD
IRONWOOD PHARMACEUTICALS INC
Award(A)Direct45K shares- - Jun 5, 2025MLTX
MoonLake Immunotherapeutics
Award(A)DirectOption to Buy
6.7K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 17, 2026 |  MLTX MoonLake Immunotherapeutics | Award(A) Option to Buy | 22,195 | - | - | Direct |
| Jun 16, 2026 |  IRWD IRONWOOD PHARMACEUTICALS INC | Award(A) | 63,481 | - | $0 | Direct |
| Jul 3, 2025 | MLTX MoonLake Immunotherapeutics | Exercise(M) | 23,500 | - | - | Direct |
| Jul 3, 2025 | MLTX MoonLake Immunotherapeutics | Sale(S) | 23,500 | $48.79 | $1,146,565 | Direct |
| Jun 10, 2025 | IRWD IRONWOOD PHARMACEUTICALS INC | Award(A) | 45,000 | - | - | Direct |
| Jun 5, 2025 | MLTX MoonLake Immunotherapeutics | Award(A) Option to Buy | 6,682 | - | - | Direct |
1-6 of 6 transactions
About Moukheibir Catherine
Moukheibir Catherine (SEC CIK 0001772130) files insider reports with the SEC as Director of MoonLake Immunotherapeutics (MLTX) and Director of IRONWOOD PHARMACEUTICALS INC (IRWD).
Signal8 holds 5 ownership filings by Moukheibir Catherine, all Form 4s, filed between Jun 9, 2025 and Jun 18, 2026. Those filings report 6 transactions, from Jun 5, 2025 to Jun 17, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Moukheibir Catherine's filings is in BOSTON, MA.
Recent filings by Moukheibir Catherine
- Jun 17, 2026: Grant or award of MLTX derivative securities (Form 4, code A).
- Jun 16, 2026: Grant or award of IRWD shares (Form 4, code A).
- Jul 3, 2025: Option exercise of MLTX shares (Form 4, code M).
- Jul 3, 2025: Open-market sale of MLTX shares (Form 4, code S).
- Jun 10, 2025: Grant or award of IRWD shares (Form 4, code A).
Other insiders filing for MoonLake Immunotherapeutics (MLTX)
- Reich Kristian, Chief Scientific Officer
- Santos da Silva Jorge, Chief Executive Officer
- Bodenstedt Matthias, Chief Financial Officer
- BVF PARTNERS L P/IL, Director
- Phillips Andrew John, Director
- Loy Spike, Director